EPHB2 and systemic lupus erythematosus: Whether EphB2, or antibodies against EphB2, play a causative role in atherosclerotic plaque formation in SLE is to be further elucidated, but its presence might partially explain the observed increased prevalence of cardiovascular events in patients with SLE compared to healthy patients [42].